Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 3/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.53 |
| ▸ | G6PD | P11413 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 13/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7177293 | 1.00 | SHBG (0.56) | SHBGGPBAR1G6PDARNR3C1 | |
| SCHEMBL7177299 | 1.00 | SHBG (0.56) | SHBGGPBAR1G6PDARNR3C1 | |
| SCHEMBL24198611 | 0.87 | SHBG (0.57) | SHBGGPBAR1ARNR3C1PGR | |
| SCHEMBL6800556 | 0.83 | G6PD (0.55) | SHBGGPBAR1G6PDNR3C1CYP19A1 | |
| SCHEMBL7184760 | 0.83 | G6PD (0.68) | SHBGGPBAR1G6PDNR3C1 | |
| SCHEMBL497499 | 0.83 | G6PD (0.68) | SHBGGPBAR1G6PDNR3C1 | |
| SCHEMBL498095 | 0.83 | G6PD (0.68) | SHBGGPBAR1G6PDNR3C1 | |
| SCHEMBL497498 | 0.83 | G6PD (0.68) | SHBGGPBAR1G6PDNR3C1 | |
| SCHEMBL6800549 | 0.83 | G6PD (0.55) | SHBGGPBAR1G6PDNR3C1CYP19A1 | |
| SCHEMBL13886300 | 0.83 | G6PD (0.55) | SHBGGPBAR1G6PDNR3C1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | SHBG 45/4885GPBAR1 205/4885G6PD 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.